Funding Opportunity RFA-RM-18-018 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to support the establishment of a Dissemination and Coordination Center (DCC) for the NIH Somatic Cell Genome Editing (SCGE) Consortium. In addition to this DCC, the Consortium will include four components (genome editing tools, delivery systems, animal models and biological assays) to produce validated techniques and knowledge through exchange of expertise, information and research tools. The DCC is expected to interact with other components of the SCGE Consortium to facilitate collaborative activities within the entire Consortium. The DCC will develop an online platform to facilitate information sharing within the Consortium, assemble resources (tools, methods, data and best practices) generated from all Consortium components into a genome editing toolkit, and disseminate the genome editing toolkit and other appropriate resources to researchers across the biomedical research community.

Funding Opportunity RFA-RM-18-017 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications proposing research on the development of novel and optimized alternatives to existing in vivo genome editing complexes.

Funding Opportunity RFA-RM-18-016 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to support the development and evaluation of innovative approaches to deliver genome editing machinery into somatic cells, with the ultimate goal of accelerating the development of genome editing therapeutics to treat human disease.

Funding Opportunity RFA-RM-18-015 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications that propose to develop and validate cell- and tissue-based platforms for assessing potential adverse biological consequences of somatic cell genome editing.

Funding Opportunity RFA-RM-18-013 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to create novel large animal reporter models for testing in vivo genome editing technologies. The deliverables from the initiative will be a set of large animal models (pigs and non-human primates), containing one or more reporter genes expressed in all cell types, that will allow facile and quantitative evaluation of genome editing in any cell type of interest. Within the Consortium, these models will be used to test new delivery systems and genome editing tools developed by accompanying components in planned Large Animal Testing Centers. The large animal models will allow investigators to optimize scale up of delivery systems and editing tools, which will be necessary for clinical trials in humans.

Funding Opportunity RFA-RM-18-012 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to create rodent reporter models for testing in vivo genome editing technologies, and to use these animal models to test genome editing delivery technologies and new genome editors developed under RFA-RM-18-016 and RFA-RM-18-017. The deliverables from the initiative will be a set of animal models (mice and rat), containing one or more reporter genes expressed in all cell types, that will allow facile and quantitative evaluation of genome editing in any cell type of interest. The Testing Centers will use these models to validate new delivery systems and genome editing tools developed by other investigators in the Somatic Cell Genome Editing Program. The creation and testing of these rodent models will accelerate the translation of genome editing technologies into treatments for human diseases.

Funding Opportunity PAR-18-585 from the NIH Guide for Grants and Contracts. This FOA invites applications for pragmatic trials for dementia care in Long-term Services and Support (LTSS) settings which will: (1) be designed to address practical comparative questions faced by Alzheimers disease (AD) and Alzheimers disease and related dementia (ADRD) patients, clinicians, and caregivers (both paid and unpaid); (2) include broad and diverse populations; and (3) be conducted in real-world settings. These trials are intended to produce results that can be directly adopted by healthcare providers, patients or caregivers for rapid translation. Successful applications will: (1) improve quality of care of persons with dementia; (2) improve quality of life for persons with dementia and their informal caregivers; (3) deliver more patient-focused, cost- effective care in LTSS; and/or (4) reduce disparities in LTSS care. This FOA will support pilot research to test the feasibility of implementing and integrating LTSS interventions (R21 phase) that, if successful, can transition to an R33 phase for implementation of large pragmatic trials. The transition from the R21 to the R33 phase of the award will be administratively reviewed and determined by successful completion of the Go/No-Go Criteria that are specified for the R21 phase.

Notice NOT-AI-18-013 from the NIH Guide for Grants and Contracts

Notice NOT-AI-18-012 from the NIH Guide for Grants and Contracts

Notice NOT-AI-18-014 from the NIH Guide for Grants and Contracts

Notice NOT-CA-18-040 from the NIH Guide for Grants and Contracts

Notice NOT-CA-18-035 from the NIH Guide for Grants and Contracts

Notice NOT-HL-18-584 from the NIH Guide for Grants and Contracts

Notice NOT-HL-18-583 from the NIH Guide for Grants and Contracts

Notice NOT-MH-18-014 from the NIH Guide for Grants and Contracts

Notice NOT-CA-18-047 from the NIH Guide for Grants and Contracts

Notice NOT-HL-18-587 from the NIH Guide for Grants and Contracts

Notice NOT-CA-18-037 from the NIH Guide for Grants and Contracts

Notice NOT-NS-18-038 from the NIH Guide for Grants and Contracts

Notice NOT-MH-18-020 from the NIH Guide for Grants and Contracts